Asia Pacific Lateral Flow Assay Market Forecast to 2028 – COVID-19 Impact and Regional Analysis - by Product Type (Kits & Reagents and Lateral Flow Readers), Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environment Testing, and Dru

Asia Pacific Lateral Flow Assay Market Forecast to 2028 – COVID-19 Impact and Regional Analysis - by Product Type (Kits & Reagents and Lateral Flow Readers), Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environment Testing, and Drug Development & Quality Testing), Technology (Sandwich Assays, Competitive Assays, and Multiplex Detection Assays), End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Diagnostics Laboratories, Homecare, Veterinary Clinics, and Others)

The Asia Pacific lateral flow assay market is expected to grow from US$ 1,332.51 million in 2023 to US$ 1,858.39 million by 2028. It is estimated to register a CAGR of 6.9% from 2023 to 2028.

Evolving Applications of Lateral Flow Assays Fuels Asia Pacific Lateral Flow Assay Market

Lateral flow assays are widely used for infectious disease diagnosis, heart disease diagnosis, and veterinary applications. However, the scope of their applications has expanded in recent years. Behavioral health, saliva-based diagnostics, biological warfare (detection of Bacillus anthracis), environmental testing (detection of contaminating enzymes in production facilities), agriculture (detection of genetically modified organisms and quality control of plants), and food microbiology (detection of E. coli O157, Salmonella, Listeria, and other food spoilage bacteria) have emerged as new application areas of lateral flow assays.

Atlas-Link Biotech (Beijing) provides FASPIT Antigen Saliva Test Kit. NOVA Test SARS-CoV-2 This colloidal gold immunochromatography-based test kit is a lateral flow assay that uses the double-antibody sandwich method to detect the SARS-CoV-2 nucleocapsid protein from saliva specimens from patients who are suspected of SARS-CoV-2 by a healthcare provider. Only certified laboratories that meet the requirements for performing moderate, high, or waived complexity tests can perform such saliva-based tests. The SARS-CoV-2 antigen saliva test kits provide preliminary test results, with negative results that don’t preclude SARS-CoV-2 infection.

Asia Pacific Lateral Flow Assay Market Overview

The Asia Pacific lateral flow assay market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Countries such as China, Japan, and India are expected to be among the largest contributors to the market in this region due to rising incidences of noncommunicable diseases and increasing strategic developments by market players in these countries. Additionally, the region holds huge potential for the Asia Pacific lateral flow assay market players to grow during the forecast period. China, a developing country in Asia Pacific, has a well-established healthcare system and a fast-growing pharmaceutical industry. It is home to various medical, pharmaceutical, and biotechnology product manufacturing companies operating in the global market. These companies are developing kits and devices for testing various infections and diseases. In China, there was an exponential rise in the incidence of human brucellosis from 2020 to 2021. As per a report published by the Chinese Center for Disease Control and Prevention, 69,767 cases of brucellosis were reported in 2,083 counties in Mainland China in 2021, a 47.7% increase from 2020 (47,425 cases). In 2017, the Chinese Pathogen Identification Net (China PIN) was developed to collect data on bacterial pathogens from the network laboratories to support the early detection and tracing of infectious diseases. Further, the COVID-19 pandemic boosted the market growth in China. As per the report published in eClinicalMedicine, lateral flow device (LFD) viral antigen immunoassays have been developed as diagnostic tests for SARS-CoV-2 infection. Thus, the fast-growing pharmaceutical industry, increasing bacterial infection and H. pylori cases in China, and rising demand for rapid test kits for COVID-19 propel the Asia Pacific lateral flow assay market growth.

Asia Pacific Lateral Flow Assay Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Lateral Flow Assay Market Segmentation

The Asia Pacific lateral flow assay market is segmented on the basis of product type, application, technology, end user, and country.

Based on product type, the Asia Pacific lateral flow assay market is segmented into kits & reagents and lateral flow readers. The kits & reagents segment held a larger share of the market in 2023. The market for lateral flow readers is sub-segmented into portable/handheld readers and benchtop readers.

Based on application, the Asia Pacific lateral flow assay market is segmented into clinical testing, veterinary diagnostics, food safety & environment testing, and drug development & quality testing. The clinical testing segment held the largest share of the market in 2023. The market for veterinary diagnostics is sub-segmented into companion animals, and livestock animals and livestock. The market for the drug development & quality testing segment is further segmented into infectious diseases testing, cardiac marker testing, pregnancy and fertility testing, cholesterol testing/ lipid profile, drug of abuse testing, and others.

Based on technology, the Asia Pacific lateral flow assay market is segmented into sandwich assays, competitive assays, and multiplex detection assays. The sandwich assays segment held the largest share of the market in 2023.

Based on end user, the Asia Pacific lateral flow assay market is segmented into hospitals & clinics, pharmaceutical & biotechnology companies, diagnostics laboratories, homecare, veterinary clinics, and others. The hospitals & clinics segment held the largest share of the market in 2023.

Based on country, the Asia Pacific lateral flow assay market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The China dominated the market in this region in 2023.

Abbott Laboratories, Access Bio Inc, bioMerieux SA, Bio-Rad Laboratories Inc, Danaher Corp, Hoffmann-La Roche Ltd, Hologic Inc, Merck KGaA, Qiagen NV, and Thermo Fisher Scientific Inc are the leading companies operating in the Asia Pacific lateral flow assay market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific lateral flow assay market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific lateral flow assay market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.